Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andrew D. Goldberg
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Beta
- 2.31
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -2.63
Financials
Net Income
$-74.77MEBITDA
$-74.43MFree Cash Flow
$-10.79MEPS (diluted)
$-0.80Shares Outstanding (diluted)
93.51M+685360.7%Operating Expenses
$18.39MCash & Debt
$187.30MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-54.65M | $-1.25 |
| 2024 | $0.00 | $-39.83M | $-1.24 |
| 2023 | $0.00 | $-29.82M | $-1.50 |
| 2022 | $0.00 | $-42.35M | $-3.95 |
| 2021 | $0.00 | $-33.15M | $-4.05 |
| 2020 | $0.00 | $-14.66M | $-5.39 |
| 2019 | $0.00 | $-16.39M | $-39.15 |
| 2018 | $0.00 | $-12.69M | $-72.29 |
| 2017 | $0.00 | $-10.58M | $-441.47 |
| 2016 | $5.06M | $-20.13M | $-1478.66 |
| 2015 | $18.16M | $-16.80M | $-1413.63 |
| 2014 | $27.12M | $-26.24M | $-3189.89 |
| 2013 | $29.88M | $-31.85M | $-4772.10 |
| 2012 | $20.09M | $-21.10M | $-3432.80 |
Valuation
ACHVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·12d ago·Neutral
…arketing and Communications SEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Kaitlyn (Kait) Tuson as Senior Vice President, Marketing and Communications. Tuson joins Achieve's executive team and will lead its m…
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
…f New Hire Inducement Awards SEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that its board of directors approved stock option grants to purchase an aggregate of 46,500 shares of its common stock and restricted stock unit (“RSU”)…
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
… for Smoking and E-Cigarette Cessation at CHEST 2026 SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST …
View source ↗ - Newsseekingalpha.com·26d ago·Negative
…etup Remains Constructive (Rating Downgrade) Achieve Life Sciences is rated a 'buy' as it nears a second NDA resubmission after resolving prior manufacturing issues. ACHV's FDA setback was manufacturing-related, not efficacy or safety, with two successful Phase 3 trials and over 1,500 exposures supporting its profile. ACHV is well-capitalized, holding $188 million in cash post-private placement, sufficient to fund the NDA resubmission and initial launch activities.
View source ↗ - Newsseekingalpha.com·27d ago·Positive
…igating a manufacturing reset for cytisinicline following a Complete Response Letter citing facility compliance, not efficacy or safety concerns. I remain bullish on ACHV, contingent on resolving manufacturing issues and leveraging a funded transition to commercialization, not market expansion or first-line displacement. ACHV's cash runway, bolstered by $180M upfront financing, appears sufficient through potential FDA approval in 1H 2027, but dilution and arbitration risks must be monitored.
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
…ces Announced Granting of New Hire Inducement Awards SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve's board of directors approved stock option grants to purchase an aggregate of 315,000 shares of its common stock and restricted stock unit …
View source ↗
Earnings
Thu, Nov 5(in 2 weeks)
Consensus estimate $-0.20 per share
Typical surprise -3.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.80 vs $-0.16miss
- Tue, May 12$-0.19 vs $-0.30beat
- Tue, Mar 24$-0.28 vs $-0.27miss
- Thu, Nov 6$-0.28 vs $-0.24miss
- Thu, Aug 7$-0.37 vs $-0.37beat
- Tue, May 13$-0.37 vs $-0.37beat
Estimates and results for ACHV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACHV officers and directors.
- Bought
- $57k
- Sold
- $1.3m
2 trades
7 trades
- Stewart Richard Alistairsold
- Oki Mark Ksold
- Stewart Richard Alistairsold
- Wan Jerrysold
- King Thomas Braxtonsold
- Jacobs Cindysold
- Xinos Jaimesold
- Oki Mark Kbought
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACHV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.